SGLT2 (sodium-glucose cotransporter-2) inhibitors have demonstrated improved cardiovascular and renal outcomes in patients with type 2 diabetes (T2D), most strikingly with a significant reduction in hospitalization for heart failure (HF).1–3 Recently, the SGLT2 inhibitor dapagliflozin has been shown to cause a reduction in death and HF hospitalization in patients with HF with reduced ejection fraction irrespective of T2D status.4 One notable feature from these outcome trials was the evidence of early benefit (<3 months). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.